Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02966353
Title Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)
Acronym REALISE
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries TUR | ITA | GRC | ESP | DEU | CAN | BGR | BEL | AUT

Facility Status City State Zip Country Details
Novartis Investigative Site Vienna A-1090 Austria Details
Novartis Investigative Site Antwerpen 2060 Belgium Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Sofia 1413 Bulgaria Details
Novartis Investigative Site Sofia 1756 Bulgaria Details
Novartis Investigative Site Vancouver British Columbia V5Z 1M9 Canada Details
Novartis Investigative Site Halle S 06120 Germany Details
Novartis Investigative Site Athens GR 115 27 Greece Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Firenze FI 50134 Italy Details
Novartis Investigative Site Palermo PA 90127 Italy Details
Novartis Investigative Site Bunkyo ku Tokyo 113-8431 Japan Details
Novartis Investigative Site Moscow 125167 Russian Federation Details
Novartis Investigative Site Moscow 129110 Russian Federation Details
Novartis Investigative Site Petrozavodsk 185019 Russian Federation Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Alicante Comunidad Valenciana 03010 Spain Details
Novartis Investigative Site Santiago de Compostela Galicia 15706 Spain Details
Novartis Investigative Site Istanbul 34093 Turkey Details
Novartis Investigative Site Kocaeli 41380 Turkey Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field